Blood glucose tracking is the single most-requested Apple Watch feature that still doesn’t exist, and it resurfaces every rumor cycle. Ahead of the Apple Watch Series 12, expected in September 2026, it’s worth answering directly: is this finally the year? As of August 2026, the honest answer is no — but the story behind why is more interesting than a simple “not yet.”
The Short Answer
No Apple Watch tracks blood glucose in 2026, and none is expected to this year. This applies to the current Apple Watch Series 11 and to the rumored Apple Watch Series 12, which is expected at Apple’s confirmed 9 September 2026 event. Bloomberg’s Mark Gurman — generally the most reliable source on unannounced Apple products — has reported that Apple remains genuinely committed to the underlying research, but that a shipping feature is not expected on the Series 12.
Why This Rumor Keeps Coming Back
Apple’s interest in glucose sensing isn’t new speculation dreamed up for 2026. Reporting traces serious internal research back to at least the mid-2010s, with claims of a dedicated biomedical engineering team working on optical glucose sensing dating to around 2017. That’s nearly a decade of on-and-off reporting about a feature that still hasn’t shipped, which is itself the clearest signal of how hard the underlying problem actually is.
Every year the Apple Watch gets a new generation, the rumor resurfaces because glucose monitoring would be a genuinely category-defining feature — not just for the ~38 million Americans with diabetes, but for the much larger population interested in metabolic health and blood-sugar trends generally. It’s a feature with obvious mass-market pull, which is exactly why it keeps generating headlines even without progress to report.
Why Non-Invasive Glucose Sensing Is Genuinely Hard
This is the part most rumor coverage skips, and it’s worth understanding because it explains why “just add a sensor” isn’t realistic.
Existing glucose monitors are invasive. Devices like the Abbott FreeStyle Libre and Dexcom G7 — the current standard for continuous glucose monitoring — work by inserting a small filament sensor under the skin that sits in interstitial fluid and measures glucose directly. That’s a fundamentally different (and easier) engineering problem than sensing glucose through unbroken skin from the outside, which is what a truly “non-invasive” Apple Watch feature would require.
Optical sensing has to isolate a weak signal. Non-invasive approaches typically rely on optical methods — shining light into tissue and analyzing how it’s absorbed or scattered — similar in principle to how the Watch already measures heart rate and blood oxygen. Glucose concentration changes affect that signal much more subtly than heart rate does, and the true glucose signal is easily swamped by noise from hydration levels, skin temperature, blood flow changes, motion, and individual differences in skin and tissue composition.
Accuracy demands are higher than for other Watch metrics. A wrist-based heart-rate reading that’s occasionally off by a few beats per minute is a minor inconvenience. A glucose reading that’s meaningfully wrong could lead to a genuinely dangerous decision for someone managing diabetes. That raises both the engineering bar and the regulatory bar — the FDA treats glucose-monitoring accuracy claims with real scrutiny, and rightly so.
No one has cracked this for consumer hardware yet. As of 2026, no company — not Apple, not Samsung, not any smaller wearable maker — has an FDA-cleared, fully non-invasive glucose sensor on the market for consumers. This isn’t Apple lagging a competitor; it’s an unsolved problem industry-wide at consumer scale and price point.
Apple’s Patent Trail: Evidence the Research Is Real
Skeptics reasonably ask whether “Apple is working on glucose tracking” is just recycled rumor-mill filler. The patent record suggests otherwise, even if it doesn’t tell us when (or if) a product ships. Apple has filed multiple patents over the years covering optical glucose sensing methods, including approaches using infrared spectroscopy and Raman spectroscopy — techniques that analyze how light interacts with tissue to infer chemical composition, glucose included. Patent filings aren’t proof of an imminent product (companies patent far more than they ship), but a sustained pattern of filings over nearly a decade is a stronger signal of serious internal investment than a single leak or analyst note would be.
Reporting has also described a dedicated internal effort — sometimes referred to as Apple’s glucose team, operating for years under tight secrecy even by Apple’s standards — that has gone through leadership changes without being shut down. A project surviving multiple leadership transitions over a decade suggests continued executive-level belief in the eventual payoff, even as the timeline keeps sliding.
What “Good Enough to Ship” Would Actually Require
It’s worth being concrete about the bar Apple would need to clear before announcing this feature, because it explains the caution:
- Clinical-grade accuracy across diverse skin tones, hydration levels, and body types. A feature that works well on some wrists and poorly on others isn’t shippable at Apple’s scale.
- Regulatory clearance. Given the health stakes, any glucose-adjacent claim would almost certainly need FDA engagement, similar to how Apple pursued clearance for ECG and, more recently, hypertension notifications. That process alone can take years.
- A defensible legal position. Continuous glucose monitor makers like Dexcom and Abbott hold significant IP in this space; any Apple entry would need to navigate that landscape carefully.
- A feature Apple is confident won’t need to be walked back. Apple has historically preferred to under-promise on health features (note how cautious the hypertension notification language is) rather than ship something and face credibility damage if it’s later found to be unreliable.
Each of these alone can add months or years; together, they help explain why a rumor with this much sustained interest still hasn’t turned into a product after nearly a decade.
What Apple Has Actually Shipped So Far
It’s worth separating what’s real from what’s rumored. The Apple Watch does have real, shipped metabolic and cardiovascular health features: heart rate, blood oxygen (on eligible models), ECG for heart rhythm, and hypertension notifications on newer models. None of these are glucose tracking, and Apple has never marketed or implied that any current Watch estimates blood sugar. If you see a third-party app or accessory claiming to turn your Apple Watch into a glucose monitor without a separate, dedicated glucose sensor, treat that claim with real skepticism — it isn’t something Apple’s current hardware is capable of.
Realistic Timeline: When Might This Actually Ship?
There’s no confirmed date, and treating any specific year as certain would be dishonest. Here’s what the more careful reporting says:
- Series 12 (2026): Not expected. Multiple sources agree on this.
- Series 13 (2027): Floated by analyst Jeff Pu as a possible candidate, but explicitly speculative — Pu’s own framing leaves real room for it to slip further.
- Beyond 2027: Given the decade-long history of this rumor consistently sliding, a cautious reader should treat any date past 2027 as equally plausible as 2027 itself.
The most defensible summary: Apple is very likely still working on this, the underlying science is genuinely difficult, and no specific ship year should be treated as reliable until Apple confirms it directly — probably via an FDA clearance announcement rather than a quiet feature drop, given the regulatory stakes involved.
Is Anyone Else Closer?
Apple isn’t the only company chasing this. Samsung has explored glucose-sensing research for the Galaxy Watch lineup, and various smaller startups have claimed breakthroughs in non-invasive sensing over the years — none of which have translated into an FDA-cleared, mass-market consumer product as of 2026. Some companies market “glucose trend” or “metabolic insight” features on smart rings and watches that are explicitly not calibrated blood glucose readings, often relying on indirect proxies like heart rate variability or continuous glucose monitor integration (pairing with a separate invasive CGM sensor rather than sensing glucose independently) rather than true non-invasive sensing. If a product ever markets itself as providing calibrated blood glucose numbers from an optical wrist or ring sensor alone, that would be a genuine industry first worth scrutinizing closely — treat such a claim as extraordinary until backed by regulatory clearance, not just a press release.
What to Use Instead, Right Now
If you need actual blood glucose data today, a dedicated continuous glucose monitor like the Dexcom G7 or FreeStyle Libre remains the only clinically validated option — talk to a doctor about access, since these are medical devices, not consumer wearables. For general metabolic and activity health tracking on your wrist in the meantime, the current Apple Watch Series 11 covers heart rate, ECG, and sleep tracking well, and if you want to compare it against non-Apple options, our Apple Watch alternatives guide covers the field.
Bottom Line
Treat “Apple Watch blood glucose tracking” as a real, long-term research effort with genuine engineering substance behind it — not vaporware — but not something to factor into a 2026 buying decision. If you’re deciding whether to buy or upgrade an Apple Watch this year, do it based on the features that actually exist today: heart rate, ECG, sleep tracking, and fall/crash detection, not a feature that has now been “almost here” for the better part of a decade.
We’ll update this article the moment Apple confirms anything official about glucose tracking on any Watch model.
Sources: MacRumors, TechRepublic, PhoneArena.